Gilead ends promising PhIII leukemia study early; Arrowhead touts hep B data;

@FierceBiotech: RIP: Failure-prone KaloBios pulls the plug, calls in the liquidators. More | Follow @FierceBiotech

@JohnCFierce: Did Sanofi ($SNY) drag its feet on Lemtrada to save on the CVR? (Or is it just a lousy drug?). More from the NYT | Follow @JohnCFierce

@DamianFierce: Bloomberg's use of up-style headlines has resulted in a piece of art. Item | Follow @DamianFierce

> Gilead ($GILD) announced today that it is ending its Phase III chronic lymphocytic leukemia study for a Zydelig combo after the treatments based on its superiority to bendamustine/rituximab. Release

> Pasadena, CA-based Arrowhead Research ($ARWR) presented Phase IIa data for ARC-520 demonstrating a reduction in hepatitis B viral antigens. Release

Medical Device News

@FierceMedDev: ICYMI: Crime syndicates are hacking devices to steal private medical information for profit. Article | Follow @FierceMedDev

@VarunSaxena2: @HillaryClinton says Medicare should negotiate for lower drug prices. @BernieSanders rips Big Pharma, too. Uh oh! | Follow @VarunSaxena2

@EmilyWFierce: Gilead scores additional indications for Harvoni in hep C, HIV patients. FiercePharma story | Follow @EmilyWFierce

> J&J to launch suite of orthopedics 'solutions' for outpatient joint replacement. Report

> SurgiQuest snapped up for $265M ahead of proposed IPO, rounding out Conmed surgical offerings. Article

> Omada Health trumpets promising results from study of digital health program in Medicare patients. More

Pharma News

@FiercePharma: Bioprinting winning converts in Singapore. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: ICYMI: Roche whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Story | Follow @EricPFierce

@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. More from FiercePharmaMarketing | Follow @CarlyHFierce

> History suggests a Pfizer-Allergan hookup would mean sizable cuts in manufacturing. Story

> Big three PBMs cut loose more specialty pharmacies as scrutiny grows. Report

> Dealmaking drugmakers 'blacklist' investors to fend off activists. Article

Animal Health News

> Heska beats the Street on revenue and earnings in Q3. More

> Aratana unveils branding and partnering plans at investor day. Report

> Merck reiterates dedication to animal health with Harrisvaccines acquisition. Article

> Phibro seeks growth in aquaculture as Q1 sales growth slows. Story

> ImmuCell soars on Q3 sales growth. Item

Biotech IT News

> Datatrak accused of 'shameless and amateurish scare tactics' as proxy fight turns nasty. Report

> What represents success to 23andMe's Wojcicki? Developing a cure for a major disease. More

> WuXi NextCODE lands starring role in 100,000 Genomes Project. Story

> FDA starts beta testing 'the most advanced bioinformatics platform in the world.' More

> Data-gathering implantable chips to be tested in schizophrenia trial. Article

Pharma Marketing News

> Depomed's staffed-up Nucynta salesforce starts bringing home the bacon. Report

> Merck to forge ahead with CETP-inhibiting cholesterol med. Item

> *NSYNC's Joey Fatone lends pearly whites to Colgate diabetes campaign. Story

> Snafus waiting to happen? Pharma's digital silos stymie end-to-end promo management. More

> Boehringer ups the ante in IPF drug race with awareness funding. Article

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.